Maria, Vasco A.Silva, J. A. daVictorino, Rui M.2021-01-202021-01-201989-11J Rheumatol. 1989 Nov;16(11):1484-14850315-162Xhttp://hdl.handle.net/10451/45882Copyright © 1989 by The Journal of Rheumatology Publishing Co. Ltd.Agranulocytosis and liver injury is described in a patient with Reiter's syndrome of 3 years duration who received pyrazinobutazone for 6 weeks before the development of the clinical picture reported. Other causes of agranulocytosis and hepatic damage were excluded and a lymphocyte transformation test to the drug revealed significant lymphocyte proliferation in response to the drug. This suggests a hypersensitivity reaction as the mechanism for this previously unrecognized association of adverse effects to pyrazinobutazone.engPyrazinobutazoneReiter's syndromeAgranulocytosisHepatitisDrug hypersensitivityjournal article1499-2752